Echinacea and Preterm Labor: A Natural Remedy by Estes, Jordan Anne & NC DOCKS at Appalachian State University
      
ECHINACEA AND PRETERM LABOR: A NATURAL REMEDY 
 
A Thesis 
by 
JORDAN ANNE ESTES 
Submitted to the Graduate School 
at Appalachian State University 
in partial fulfillment of the requirements for the degree of 
MASTER OF SCIENCES 
May 2013 
Department of Biology 
  
 
ECHINACEA AND PRETERM LABOR: A NATURAL REMEDY 
A Thesis 
by 
JORDAN ANNE ESTES 
May 2013 
APPROVED BY: 
Chishimba Nathan Mowa, Ph. D. 
Chairperson, Thesis Committee 
Maryam Ahmed, Ph. D. 
Member, Thesis Committee 
Dru A. Henson, Ph. D. 
Member, Thesis Committee 
Susan L. Edwards, Ph. D. 
Chairperson, Department of Biology 
Edelma D. Huntley, Ph. D. 
Dean, Research and Graduate Studies 
 
Copyright by Jordan Anne Estes 2013 
All Rights Reserved 
 
iv 
 
Abstract 
ECHINACEA AND PRETERM LABOR: A NATURAL REMEDY 
Jordan Anne Estes,  
B.S., Lenoir-Rhyne University 
M.S., Appalachian State University 
Chairperson: Chishimba Nathan Mowa 
 Causally, premature births largely result from inflammation and current treatments 
are either unsafe or ineffective. Here, our goal was to test whether the use of natural products 
[Echinacea purpurea (L.) Moench, root extract] with anti-bacterial and -inflammatory 
activities and a long history of safe use could attenuate induction of inflammation in the 
cervix (birth canal). Studies using three different complementary models, specifically non-
pregnant in vivo, non-pregnant ex vivo and preterm labor models, were conducted.  We also 
sought to decipher mechanisms likely to mediate Echinacea’s anti-inflammatory activities by 
blocking the activity of heme-oxygenase-1 (HO-1).  Tissues were harvested and evaluated 
using real time-PCR, Western blot and/or histology. Here, we compare the suitability of the 
three models and show that Echinacea attenuates levels of the activated (phosphorylated) 
master inflammation transcription factor, nuclear factor kappa B (NFκB), and expression of 
select pro-inflammatory cytokines associated with inflammation-induced preterm labor. We 
also show that HO-1 may mediate Echinacea’s anti-inflammatory activities in the cervix.  
These findings are significant as they provide important data that could potentially lead to the 
development of natural strategies for modulating infection-induced preterm labor. 
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Introduction 
Overview 
 Premature labor is a common and costly health care condition, the magnitude of 
which is staggering.  Every minute approximately 1,400 babies are born prematurely 
throughout the world and over 100 of these infants die (Beck et al. 2010).  Causally, half of 
these premature births are known to result from precocious and abnormal presence of 
infection-induced inflammatory factors, such as tumor necrosis factor alpha (TNFα), during 
contractions and cervical (birth canal) opening.  While the exact mechanisms that underlie 
cervical opening are not completely understood, it may be secondary to a microbial infection 
triggering the induction of inflammation (Romero et al. 2006).  Current therapies for preterm 
labor are either unsafe to the fetus and/or mother, or are ineffective, so it is imperative that 
safe and effective therapies are developed to address this unmet medical need.  
 Plant extracts with a long history of safe use and well documented anti-microbial and 
anti-inflammatory activities, such as Echinacea, could potentially be used to attenuate 
inflammation-induced preterm labor in high-risk women (Barrett 2003, Goel et al. 2004, 
Barnes et al. 2005, Shah et al. 2007). Interestingly, Echinacea has been shown to decrease 
levels of some preterm labor-inducing or associated pro-inflammatory cytokines, such as 
TNFα, interleukin-1 (IL-1), and IL-6, in non-reproductive tissues (Burger et al. 1997, 
Rininger et al. 2000, Kim et al. 2002), in part, by attenuating expression of a plethora of 
cytokines (Burger et al. 1997, Rininger et al. 2000, Kim et al. 2002, Zhai et al. 2007).  It is, 
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therefore, feasible to speculate that Echinacea could potentially be used to modulate 
infection-induced preterm labor.   
Basics of Cervical Remodeling and the Birth Process 
 During pregnancy, the quiescent uterus provides a favorable environment for the 
growing fetus and the non-pliable cervix ensures retention of the fetus in utero. However, at 
term the cervix undergoes tissue remodeling or cervical ripening with a progressive 
dissociation and disorganization of collagen fibers and bundles that leads to softening and 
dilation of the cervix. At this time the uterus begins to contract and the cervix relaxes, and, 
collectively, these alterations facilitate a timely passage of the fetus at parturition (Kelly 
2002). Failure or disruption of these processes causes complications at parturition, such as 
preterm or protracted labor, that account for 75% of all infant deaths (Challis 2000).  
 
Physiological Changes Associated with Labor and Delivery in the Cervix 
The cervix is a fibrous, connective tissue mainly composed of collagen and 
proteoglycans (Sennstrom et al. 2000).  Cervical remodeling occurs in two general steps, the 
first being a slow stage, which extends over much of pregnancy, followed by a final rapid 
process, immediately preceding labor (Sennstrom et al. 2000).  The slow process shows a 
change in the turnover of matrix components, which results in reorganization of the 
collagenic fibrillar network, while the final ripening state shows an influx of neutrophils 
capable of secreting collagenase and elastase (Sennstrom et al. 2000).   During cervical 
remodeling, there is a 50-70% decrease in collagen and proteoglycan concentration, with an 
increase in collagen synthesis and this increased proteolytic activity coincides with an 
increase in solubility of collagen (Sennstrom et al. 2000).   Cervical remodeling is also 
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characterized by an increased accumulation of leukocytes in the cervical stroma before the 
onset of labor (Thomson et al. 1999, Young et al. 2002).  These leukocytes are responsible 
for the breakdown and subsequent remodeling of cervical tissue via the release of matrix 
metalloproteinases, prostaglandins, cells adhesion molecules, and nitric oxide (NO) 
(Thomson et al. 1999, Osman et al. 2003).   
Pro-inflammatory cytokines, such as IL-1β, IL-6, IL-8 and TNFα, have been 
identified in reproductive tissues during labor (Young et al 2002).  In the cervix, each of 
these cytokines has been found in different locations within the tissue (Young et al. 2002).  
For example, IL-1β, IL-6, IL-8 and TNFα have all been shown to be localized to a 
subpopulation of leukocytes (possibly neutrophils), as well as glandular epithelial cells, 
luminal epithelia and stromal cells within the cervix (Young et al. 2002).  It has been 
suggested that the invading leukocytes are principally responsible for the noted increase in 
these pro-inflammatory cytokines (Young et al. 2002, Osman et al. 2003).  However, for the 
most part, their specific underlying mechanisms and function under physiological conditions 
remain obscure; it is unclear whether they are simply the byproducts of another 
pathophysiological event (Young et al. 2002).  Either way, it is likely that they do function to 
stimulate uterine activity, either directly or indirectly, via perhaps an increase in 
prostaglandin production, attraction of leukocytes, membrane rupture and/or tissue 
remodeling under pathological conditions, notably during infection (Young et al. 2002).  
Specifically, IL-1β and TNFα stimulate arachidonic acid release and the subsequent 
prostaglandin production in human myometrial cells, which then stimulate myometrial 
contractions and ultimately ripening of the uterine cervix (Young et al. 2002).  IL-1β and 
TNFα are also known to increase production of matrix metalloproteinase-9 in human 
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myometrial smooth muscle cells and may therefore play a role in precocious tissue 
remodeling associated with obstetrical complications, such as preterm labor (Young et al. 
2002).   
 
Preterm Labor 
In humans, preterm labor is defined as labor occurring prior to 37 weeks gestation 
(Simhan & Caritis 2007) and is the leading cause of death in children under 5 years of age, 
second only to pneumonia (Blencowe et al. 2012).   
 
Epidemiology: According to the World Health Organization, 15 million babies are born 
prematurely each year worldwide, with the majority of these births coming from Nigeria, 
China, India, the United States and Brazil (Blencowe et al. 2012).  Currently, the global 
average percentage of preterm birth rate is 11.1% (Wen et al. 2004) and according to the 
March of Dimes report card, in 2012 the United States (US) earned a grade of “C” at 11.7% 
(March of Dimes, 2012).The US intends to reduce its rate down to 9.6% by 2020 (March of 
Dimes, 2012).  Nationally, Mississippi has the highest rate at 16%, while Vermont has the 
lowest rate, at 8%.  North Carolina’s rate is at 12.6%, earning it a grade of “C” and is slightly 
higher than the national average (March of Dimes, 2012).  Premature births cost the United 
States healthcare system $26 billion a year (Beck et al. 2010).   
 
Preterm Labor Biology:  Pathogenesis: While nearly 40% of premature births have an 
unknown cause, studies suggest that there are four main causes of spontaneous preterm labor, 
namely: a) maternal and/or fetal stress, b) bleeding, c) stretching and d) 
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infections/inflammation (Goldenberg et al. 2002, Simhan & Caritis 2007, Beck et al. 2010).  
Chronic psychosocial stress of the mother or physical stress in the fetus induce production of 
corticotropin-releasing hormone (CRH), which in turn may trigger other hormones, such as 
prostaglandins, which trigger uterine contractions and eventually preterm birth (Goldenberg 
et al. 2002).  Uterine bleeding as a result of complications such as placental abruption 
(placenta peels away from the uterine wall before delivery), which may trigger release of 
proteins involved in clotting, such as thrombin, which in turn stimulates uterine contractions 
(Goldenberg et al. 2002).  Uterine distension by multi-fetal pregnancies may lead to 
increased gravitational weight exerted on the cervix and a positive feed-forward release of 
the hormone oxytocin, which stimulates uterine contractions (Goldenberg et al. 2002).  The 
bulk of preterm labor is induced by bacterial infections that lead to inflammation and preterm 
labor and account for the preterm premature rupture of membranes (PROM) (25-40%), and 
obstetrically indicated preterm delivery (20-25%) (Goldenberg et al. 2002, Wen et al. 2004).   
Risk factors: Several lifestyles and factors have been identified to put a woman at risk 
for preterm birth, including: a) a history of preterm birth; b) size or multi-fetal pregnancies; 
c) certain uterine or cervical abnormalities (such as shortened cervix); d) ethnicity, with the 
highest rate in black women; e) age, with teenage or older mothers at the greatest risk; f) 
education and socio-economic status highest in women with low education and socio-
economic status; g) habits, such as cigarette smoking increase the risk; h) marital status: 
unmarried women or those not living with a partner are at a higher risk; i) occupation: 
women with stressful occupations are at a higher risk; j) body weight: low maternal pre-
pregnancy body mass index, and poor or excessive weight gain increase the likelihood of a 
preterm birth (Goldenberg et al. 2002, Wen et al. 2004).  Of all these risk factors cited above, 
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the top three are: a) history of preterm birth, b) size or multi-fetal pregnancies, and c) certain 
uterine or cervical abnormalities (such as shortened cervix) (Goldenberg et al. 2002, Wen et 
al. 2004). 
Diagnostics: Risk scoring systems, uterine contraction monitoring, cervical 
sonography and fetal fibronectin testing are several tools frequently utilized in the prediction 
and early detection of preterm birth, with the most promise seen from cervical length 
measurement and fibronectin tests (Wen et al. 2004).   Cervical length is determined using 
trans-vaginal ultrasound (Shennan & Jones 2004).  According to cervical assessments in 
women without contractions, studies of both lower- and higher-risk women have shown that 
the shorter the cervix (less than 25 mm), the more likely a preterm birth will occur (Shennan 
& Jones 2004).  Fetal fibronectin is produced by fetal and placental tissue and acts as the 
“glue” that adhere the placental membranes to the endometrium and is normally detected in 
vaginal secretions up to week 22 of gestation, and again 1 to 3 weeks before delivery (Iams 
2003, Shennan & Jones 2004).   Fibronectin found in cervicovaginal secretions after 22 
weeks is an indicator of disruption of the decidual-chorionic interface and has been shown to 
be associated with a six-fold increased risk of preterm birth before 35 weeks, and a 14-fold 
increased risk of preterm birth before 28 weeks (Iams 2003).  In addition to cervical 
measurements and fetal fibronectin tests, there are various but less reliable markers that can 
be used to predict spontaneous preterm birth (Kim et al 2011).  These include leukocyte 
differential counts and neutrophil to lymphocyte ratio (Kim et al 2011), levels of serum IL-6 
and TNFα, which are elevated during preterm labor, IL-1β, IL-6, IL-8, and IL-18 in 
cervicovaginal secretions, where they are elevated during preterm labor (Kim et al 2011).   
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Current therapies: Stopping uterine contractions has been the focus of current 
therapeutic approaches, based on the assumption that clinically apparent contractions 
correspond with the initiation of labor, and therefore the prevention of contractions should 
prevent labor (Simhan & Caritis 2007).  Inhibition of myometrial contractions is called 
tocolysis, and drugs administered for such a purpose are called tocolytics (Simhan & Caritis 
2007).  The aim of this treatment regimen is to delay delivery so that interventions, such as 
corticosteroid shots can be implemented (Wen 2004).  Corticosteroids help enhance 
development of lungs and particularly secretion of pulmonary surfactant, which reduces the 
risk of neonatal respiratory distress syndrome, intra-ventricular hemorrhage, necrotizing 
entercolitis, and overall perinatal death (Wen 2004).  There are many classes of tocolytics, 
each with their own advantages and short-comings, including: a) beta adrenergic receptor 
agonists (terbutaline), b) nitric oxide (NO) donors, c) magnesium sulfate, d) calcium channel 
blockers (nifedipine), e) cyclooxygenase (COX) inhibitors (indomethacin), and f) oxytocin-
receptor antagonists (Simhan & Caritis 2007).  While tocolytics are good for temporal 
inhibition of contractions, most do not help decrease preterm birth and pose serious negative 
side effects both to the mother and fetus, notably low birth weight, neonatal complications, 
and increase in risk of death (Wen et al. 2004, Simhan & Caritis 2007).  Currently, the only 
therapy that targets the cervix to prevent spontaneous preterm birth is elective cervical 
cerclage (Wen et al. 2004).  In cerclage, a stitch is inserted in the cervix to keep it closed, and 
removed around 37 weeks of pregnancy (Wen et al. 2004).  Studies have shown that this 
procedure may have some significant effect in reducing preterm births before 34 weeks of 
gestation. However, more studies are needed to identify women who would most benefit 
from cerclage (Simhan & Caritis 2007).  Lastly, for infection-induced preterm labor, which 
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accounts for the bulk of spontaneous preterm birth and the focus of the current study, 
antibiotics are currently the treatment of choice. However, for the most part, they also have 
side effects; especially to the fetus (Wen et al. 2004). 
 
Infection/inflammation-induced preterm labor: As stated earlier, intrauterine 
infection/inflammation is frequently associated with preterm labor (Romero et al. 2002, 
Romero et al. 2006).  Studies have suggested that preterm labor is often triggered by the 
body’s response to certain bacterial infections, such as those involving the genital, urinary 
tracts and fetal membranes (Goldenberg et al. 2002).  Microorganisms may gain access to the 
amniotic cavity and fetus through many different routes, including ascension via the vagina, 
fetal membranes and amniotic cavity (Romero et al. 2006).  The entry of lower genital tract 
bacteria into the decidua trigger the recruitment of leukocytes, notably via binding to toll-like 
receptors (TLRs), ultimately leading to an increase in cytokine production (Klein & Gibbs 
2004).  
Toll-like receptors recognize foreign invaders, including microorganisms, and this 
receptor system is believed to play a significant role in infection-mediated preterm birth 
(Challis et al. 2009).  For example, TLR4 can be activated by lipopolysaccharide (LPS), a 
major cell well component of gram-negative bacteria, as well as fragments of fetal 
fibronectin (Tsan & Gao 2004, Challis et al. 2009).  LPS can activate TLR4 and trigger 
NFκB, a hallmark signal transduction pathway for innate immune responses (Chow et al. 
1999, Da Silveira Cruz-Machado et al. 2010).  NFκB is highly activated at sites of 
inflammation and can induce transcription of the pro-inflammatory cytokines previously 
described to be involved in labor (Tak & Firestein 2001).   
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Upon LPS recognition, TLR4 recruits its downstream adaptors through interactions 
with toll-interleukin-1 receptor (TIR) domains (Poltorak et al.1998).  One of the five TIR 
domain-containing adaptor proteins is myeloid differentiation primary response gene 88 
(MyD88) (O’Neill & Bowie 2007).  MyD88 also contains a death domain (DD), which can 
recruit and activate a death domain-containing kinase, IL-1 receptor associated kinase-4 
(IRAK-4) (Suzuki et al. 2002).  Another adaptor protein, TNF receptor-associated factor 6 
(TRAF-6) is critical for the MyD88-dependent pathway downstream of IRAK-4 (Lu et al. 
2008).  TRAF6 activates transforming growth factor-β-activated kinase 1 (TAK1), which 
then activates downstream IKK (IκB kinase) and mitogen-activated protein kinase (MAPK) 
pathways (Lu et al. 2008).  NFκB exists in the cytoplasm in an inactivated form associated 
with inhibitors of κB (IκB) (Tak & Firestein 2001).  Phosphorylation of IκB leads to the 
degradation of IκB proteins and translocation of the transcription factor NFκB into the 
nucleus, which controls the expression of pro-inflammatory cytokines via binding of NFκB 
to κB enhancer elements of target genes, inducing transcription of pro-inflammatory 
cytokines (Tak & Firestein 2001).  Activation of the downstream MAPK pathways leads to 
induction of another transcription factor, activator protein-1 (AP-1), which also has a role in 
the expression of pro-inflammatory cytokines (Chang & Karin 2001).   
There are three major subfamilies of MAP Kinases: extracellular signal-related kinase 
(ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK (Kyriakis & Avruch 2001).  These 
pathways can be activated by a wide variety of stimuli acting through different receptor 
families, such as hormones and growth factors acting through receptor tyrosine kinases, or 
cytokine receptors (Kyriakis & Avruch 2001).  It is generally accepted that there are many 
MAPK pathways existing in parallel and in conjunction with the NFκB pathway, and that 
 
10 
 
these pathways are important to stress and inflammatory responses, including up regulation 
of cytokines, commonly seen in the inflammation-induced preterm labor (Kyriakis & Avruch 
2001).   
Some of the relevant pro-inflammatory cytokines associated with preterm labor 
include TNFα, IL-1β, IL-6 and COX-II (Romero et al. 2006).  IL-10 is one of the many anti-
inflammatory cytokines which acts to counter-balance an overreaction from pro-
inflammatory cytokines during infection or pregnancy (Thaxton & Sharma 2010).  For 
instance, IL-10 levels are higher during preterm labor, perhaps as a response to high 
circulating levels of pro-inflammatory cytokines, such as IL-1β (a pro-inflammatory 
cytokine) (Dubicke et al. 2010).  Cytokines have been found to trigger prostaglandin 
synthesis in the amnion, chorion, decidua, myometrium, and cervix, among other things 
(Young et al. 2002, Klein & Gibbs 2004).  This then leads to uterine contractions, cervical 
dilation, membrane exposure, and greater entry of microbes into the uterine cavity.  
Cytokines, such as IL-6, have also been found to stimulate production of matrix 
metalloproteinases by the chorion and amnion (Young et al. 2002, Klein & Gibbs 2004).  
Matrix metalloproteinases are implicated in cervical ripening as well as degradation of the 
fetal membranes (Young et al. 2002, Klein & Gibbs 2004).  There has also been evidence 
supporting a relationship between periodontal disease and preterm delivery (Romero et al. 
2006).  However, intrauterine infections caused by bacteria are currently considered to be the 
leading cause of infection-induced preterm birth (Romero et al. 2006).  The most common 
microbial isolates from the amniotic cavity and intact membranes of women with preterm 
labor are Ureaplasma urealyticum (U. urealyticum), Fusobacterium species and Mycoplasma 
hominis (Romero et al. 2002, Romero et al. 2006).  In contrast, vaginal colonization by 
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organisms such as U. urealyticum and Candida species has not been shown to cause preterm 
birth. However, U. urealyticum is found in the amniotic fluid and has a prevalence of 6% of 
patients with preterm birth (Romero et al. 2006).     
Antibiotic trials to prevent preterm birth have been conducted using three different 
designs: a) antenatal treatment of lower genital tract infection caused by specific organisms; 
b) treatment of preterm labor with intact membranes; c) treatment after preterm premature 
rupture of membranes (PPROM) (Klein & Gibbs 2004).  Based on data from these trials, 
compelling evidence supports intervention in clinical practice.   
Antenatal treatment of lower genital tract infection caused by specific organisms:  
Certain organisms and/or infections have been associated with preterm birth and make up the 
list of candidate infections for antenatal treatment, such as: U urealyticum, group B 
streptococci, Neisseria (N) gonorrhoeae, Chlamydia (C)trachomatis, Trichomonas (T) 
vaginalis, bacteriuria, and bacterial vaginosis (BV) (Klein & Gibbs 2004).  Although U 
urealyticum does not appear to cause preterm birth, it can become pathogenic if it gains 
access to the upper genital tract (Klein & Gibbs 2004).  For this reason, following clinical 
trials, it was found that screening and/or treatment of lower genital U urealyticum to prevent 
preterm birth, is not helpful and should, therefore, be avoided, in the absence of upper genital 
tract infection (Klein & Gibbs 2004).  Rectovaginal group B streptococci should not be 
treated antenatally either to prevent preterm birth; however, group B streptococcal bacteriuria 
should be screened for and treated to prevent preterm birth (Klein & Gibbs 2004).  Also, the 
sexually transmitted organisms N gonorrhoeae and C trachomatis should be screened for and 
treated to prevent spread and vertical transmission (Klein & Gibbs 2004).  Screening for and 
treatment of bacteriuria in pregnancy has been found to prevent symptomatic urinary tract 
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infection as well as preterm birth (Klein & Gibbs 2004).  Women with symptomatic T 
vaginalis infections in pregnancy have successfully been treated with oral metronidazole, 
which has been shown to be safe in the first trimester of pregnancy (Klein & Gibbs 2004).  
Asymptomatic T vaginalis, however, should not be screened for or treated based on a large 
clinical trial that shows the absence of benefit as well as increased risk of preterm birth 
(Klein & Gibbs 2004).  The association between BV and preterm birth is an interesting one, 
with BV being found in 10-25% of women – BV can be diagnosed via gram stain, and 
approximately 50% of women with BV are asymptomatic.  Unfortunately, results of 
treatment trials for BV have been conflicting, with some trials showing a reduction in 
preterm birth when BV was screened for and treated and some trials showing no benefit of 
screening and treating overall (Klein & Gibbs 2004).  On the basis of a number of clinical 
studies, however, it is suggested that screening and treatment of high-risk women are 
warranted with a recommended oral regimen lasting seven days (Klein & Gibbs 2004).   
Antibiotic treatment in preterm labor with intact membranes:  Several studies have 
reported the use of antibiotics to prolong pregnancy in women in preterm labor with intact 
membranes (Kenyon et al. 2001, King & Flenady 2003).  The overall use of antibiotics, 
however, did not decrease preterm birth, delivery within 48 hours, or perinatal mortality rates 
compared to women not treated with antibiotics (Kenyon et al. 2001).  In a meta-analysis 
from the Cochrane Library, many trials were assessed, with the overall conclusion that the 
routine administration of antibiotics to women with preterm labor and intact membranes 
could not be recommended, as there were no clear improvements in neonatal outcomes and 
potentially a trend toward increased neonatal deaths (King & Flenady 2003).   
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Antibiotic treatment after preterm premature rupture of membranes (PPROM):  
Several large trials have been conducted to assess this area (Klein & Gibbs 2004).  One such 
trial assessed patients taking ampicillin and erythromycin for seven days compared to 
placebo in women with PROM from 24-32 weeks gestation, finding women given antibiotics 
were far more likely to remain undelivered at 2, 7, 14 and 21 days compared to placebo 
(Mercer et al. 1997).  Another trial showed small but significant benefits in oral antibiotic 
therapy for 10 days with erythromycin or amoxicillin or both compared to placebo (Kenyon 
et al. 2001).  As a result of comparing these studies, it has been suggested that the routing 
prescription of antibiotics (specifically erythromycin) in women with PPROM can be 
associated with better maternal and fetal outcome (Klein & Gibbs 2004).   
With mounting evidence that antibiotic treatment can be beneficial only in certain 
cases of preterm labor, the question remains as to why antibiotics do not regularly decrease 
premature birth.  There are several explanations that have been suggested, such as: a) 
bacterial lysis by antibiotics, which can hasten preterm labor; b) prescription of the wrong 
antibiotic, since the organism responsible for infection-induced preterm labor is not known in 
many cases; and most convincingly c) the fact that once clinical signs have manifested, the 
inflammatory cascade has progressed too far to be affected by antibiotics (Klein & Gibbs 
2004).  This, in conjunction with the magnitude of redundancy in the cytokine network, 
demonstrates the limitations of blocking one single factor in preventing 
infection/inflammation-induced preterm labor (Klein & Gibbs 2004, Romero et al. 2006). 
This reality calls for alternative approaches to managing infection-induced preterm labor, 
such as the use of natural remedies with anti-bacterial and –inflammatory activities, e.g., 
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Echinacea. One possible factor that mediates Echinacea’s anti-inflammatory activities, 
among others, is heme-oxygenase 1 (HO-1) in the liver (Otterbein et al. 2003). 
 
Heme oxygenase (HO)-1  
 HO-1 is an enzyme that catalyzes the breakdown of heme into three products: 
carbon monoxide (CO), biliverdin, and free iron (Otterbein et al. 2003).  HO-1 plays tissue-
protective roles under normal and physiological conditions, including anti-inflammatory, 
anti-apoptotic, and anti-proliferative actions in endothelial, epithelial and smooth muscle 
tissues, to name a few (Otterbein et al. 2003).The anti-inflammatory properties of HO-1 have 
been further supported by the fact that HO-1 deficient mice develop a chronic inflammatory 
disease state that progresses with age (Otterbein et al. 2003). 
 There is strong evidence suggesting that the by-products of heme catabolism 
mediate the protective function of HO-1 (Otterbein et al. 2000).  One study suggests that 
carbon monoxide (CO) can selectively modulate the cascade of pro-inflammatory and anti-
inflammatory cytokines. Of interest to the current study, CO has been shown to inhibit LPS-
induced production of TNFα, IL-1β, while increasing IL-10 production in these same cells 
(Otterbein et al. 2000).  In this particular study, the anti-inflammatory effects of CO involve 
the MAP kinase signaling pathway, specifically the MKK3/p38 MAP kinase pathway 
(Otterbein et al. 2000).  This is based on several observations: CO had no effect on 
ERK1/ERK2 or JNK MAP kinases.  It is also known that HO-1 is mediated by the p38 MAP 
kinase pathway in response to oxidative stress (Otterbein et al. 2000).  Unfortunately, the 
precise mechanism used by CO to modulate the MAP kinases remains unclear (Otterbein et 
al. 2000) and Echinacea’s effects and the role of HO-1 in mediating its (Echinacea) anti-
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inflammatory activities in infection-induced preterm labor in the cervix have not been 
studied.  
 
Echinacea 
Overview: Echinacea angustifolia, a member of the Compositae family and known as 
the purple coneflower, has been used for centuries by Native Americans for pain relief and 
wound treatment, an antidote against various poisons, and for symptoms associated with the 
common cold (administrative routes used unclear) (Borchers et al. 2000, Barrett 2003, 
Barnes 2005, Goel et al. 2004, Shah et al. 2007).  Of the nine species of Echinacea only 
three are used in herbal remedies, namely Echinacea (E) angustifolia, E. pallida and E. 
purpurea, referred to as Echinacea from henceforth (Hobbs 1989, McKeown 1999).  What is 
commonly called Echinacea in the United States is likely one of the three mentioned species, 
or a combination of two or even all three of them (Borchers et al. 2000).   
Biological activities: There are substantial differences in the chemical compositions 
and biological activities between different species, as well as between their roots and aerial 
parts (Borchers et al. 2000).  Recently, many of these claims have been confirmed 
experimentally using modern research technologies (Raso et al. 2002), including Echinacea’s 
anti-fungal, anti-cancer, anti-viral, antioxidant, and anti-inflammatory properties (Raso et al. 
2002, Barrett 2003). The current study focuses on Echinacea’s anti-inflammatory properties.  
For instance, Echinacea has been shown to attenuate key inflammatory pathways, notably the 
NFκB signaling pathway, which results in up-regulation of COX-II and other pro- and anti-
inflammatory cytokines (TNFα, IL-6, and IL-10) (Raso et al. 2002).  Because Echinacea has 
been shown to decrease levels of preterm labor-inducing or associated pro-inflammatory 
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cytokines, such as TNFα, IL-6, IL-10 and IL-1, in non-reproductive tissues (Burger et 
al.1997, Rininger et al. 2000, Kim et al. 2002, Zhai et al. 2007),  it is reasonable to speculate 
that Echinacea could potentially be used to modulate infection-induced preterm labor.    
 Subfractions: Within a hydro-ethanolic extract of Echinacea, there are many sub-
fractions which may be responsible for the well-documented anti-inflammatory properties.  
For example, hydro-ethanolic extract of Echinacea (which is the most commonly used 
vehicle) contains two major groups of compounds, namely caffeic acid conjugates and 
alkylamides, the two main bioactive alkylamides being dodeca-2E, 4E, 8Z, 10Z-tetraenoic 
acid isobutylamide and dodeca-2E, 4E- dienoic acid isobutylamide (Stevenson et al. 2005, 
Matthias et al. 2007).  Although these isolates have been shown to have immunomodulatory 
effects, their exact underlying pathway or their specific bioactive ingredients are yet to be 
identified (Stevenson et al. 2005, Matthias et al. 2007).  Currently, no industry 
standardization is required for the amount of individual chemical constituents in commercial 
preparations of Echinacea (Toselli et al. 2009) but many Echinacea extracts are standardized 
to cichoric acid (or total phenols), implying that cichoric acid may account for its biological 
activities (Stevenson et al. 2005, Matthias et al. 2007).   
Metabolism: Among the phytochemicals found in Echinacea, the bioavailable 
alkylamides are thought to be the compounds responsible for the immunomodulatory effects 
in the human (Toselli et al. 2009).   Human liver microsomes have been shown previously to 
degrade certain alkylamides in a time-dependent manner, suggesting that these components 
are metabolized by cytochrome p450 enzymes (Toselli et al. 2009, Toselli et al. 2010).  
There are two main groups of active compounds in the hydro-ethanolic extracts of 
Echinacea: i.e., a) lipophilic compounds, such as alkylamides, and b) hydrophilic compounds 
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mainly consisting of caffeic acid derivatives (Toselli et al. 2009).  These two main groups 
work together and are found mainly in commercial ethanolic extracts.  Alkylamide 
concentrations are highest in the roots of the plant and at least eight alkylamides present in 
hydro-ethanolic Echinacea preparations were bioavailable after oral ingestion, while, in 
contrast, caffeic acid derivatives were not detected in circulation. Absorption of alkylamides 
was found to be rapid after ingestion, and serum alkylamide concentrations typically reached 
their maximum levels 20-45 minutes after ingestion.  Another study showed plasma levels of 
people who ingested Echinacea tablets showed no caffeic acid conjugates after ingestion; 
alkylamides were rapidly absorbed and were measureable in plasma 20 minutes after 
ingestion and detectable for 12 hours afterward (Matthias et al. 2005).  These studies 
collectively suggest that caffeic acid conjugates and cichoric acid have poor bioavailability, 
leaving alkylamides as the likely mediator of Echinacea’s therapeutic effects (Matthias et al. 
2007). 
 
Purpose of Study   
In the present study, we test the effectiveness of a whole ethanolic root extract of 
Echinacea to attenuate lipopolysaccharide (LPS)-induced expression of some of the key pro-
inflammatory factors associated with precocious cervical remodeling during preterm labor 
using three mice models, namely in vivo, ex vivo and preterm labor models. Our primary 
hypothesis is that Echinacea can be used to modulate inflammation-induced precocious 
cervical remodeling.  Here, we focus on investigating Echinacea’s ability to attenuate the 
expression of pro-inflammatory factors in the cervix and their likely underlying mechanisms. 
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Methods and Materials  
Animals Used in the Study 
 Mice from Charles River, strain C57BL6/129SvEv, were used in the present study 
(n=3-7) for all the experiments described below, including Echinacea optimization (dose, 
route, frequency, duration) using the ex vivo and in vivo models and in mechanism studies, as 
described below. All animals used in ex vivo and mechanism (ex vivo + in vivo) studies were 
ovariectomized non-pregnant mice, whereas in vivo studies included both ovariectomized 
non-pregnant and preterm labor mice models (day 15 pregnant animals treated with LPS).  
Animals were housed under constant room temperature (21°C), with a 12:12h light and dark 
cycle and had free access to water and feed. All experiments were performed in accordance 
with the Guide for the Care and Use of Laboratory Animals of the local institution 
(Appalachian State University) and the NIH guidelines (NIH publication number 86-23), and 
efforts were made to minimize both animal suffering and numbers of animals used. After 
their respective treatments and prior to tissue harvest, mice were administered a lethal dose 
of sodium pentobarbital (Sleepaway®, Fort Dodge Laboratories Inc., Burlingame, CA), 
immediately followed by trans-cardio perfusion using 0.9% normal saline solution. No trans-
cardio perfusions were performed for ex vivo studies.  All uterine cervical tissues were 
carefully harvested under a stereomicroscope, to avoid tissue contamination from vaginal or 
uterine tissues, and the tissues were then processed and analyzed appropriately using various 
techniques, including Western blot analysis and real time polymerase chain reaction (real 
time PCR), as described below. Immediately following tissue harvest, tissues for ex vivo 
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studies were placed in 48 well plates containing fresh media (RPMI 1640 supplemented with 
10% Fetal Bovine Serum) and incubated, as described below.  
 
Surgery: Ovariectomies (ovary removal)  
 Before treatments or tissue harvest, sexually mature non-pregnant mice ~ 6 weeks 
old, weighing between 30-40g, were ovariectomized. Prior to surgery, animals were 
anaesthetized using a mixture of ketamine (43-129 mg/g body weight) and xylazine (8.6-26 
mg/g body weight), followed immediately after surgery by administration of Baytril® 
antibiotic (Bayer, Leverkusen, Germany), to prevent post-surgery infections. Animals were 
then allowed to rest for seven days post-surgery before performing experiments, to allow 
removal of residual ovarian sex steroid hormones, confirmed during tissue harvest by 
significant reduction in uterine size. Animals with normal uterine size, seven days after 
ovariectomy, were eliminated from the study.  
  
Optimization Studies and Treatments 
Based on previous studies, conditions were optimized for non-pregnant and pregnant 
in vivo models.  The following conditions were found to be optimal and used in subsequent 
non-pregnant in vivo experiments:  Echinacea was given at a dose of 1 mg/mouse via inter-
peritoneal (IP) injection route, followed by LPS administration at 100 µg/mouse four hours 
after Echinacea dose, and one hour prior to cervical tissue harvest, as illustrated in Figure 1.  
After treatment and prior to cervical tissue harvest, animals were euthanized with sodium 
pentobarbital (Sleepaway®, Fort Dodge Laboratories Inc., Burlingame, CA). 
 
20 
 
 
Figure 1 Illustration showing schedule of injections for non-pregnant, in vivo model 
 
Pregnant animals from day 15 of pregnancy were used and induced with preterm labor, 
based on the previously reported animal model for preterm labor - 250 μg of intra-uterine 
LPS; (Elovitz & Mrinalini 2005).  Preliminary studies in our lab also yielded optimal 
conditions for preterm model treatments, and were found to be as follows: initial injection of 
Echinacea (1 mg/mouse) at time 0 h, with boosters at times 4 h and 8 h, respectively, with 
animals euthanized at time11 h post initial Echinacea injection, as shown in Figure 2 below. 
LPS was administered one hour after the last booster of Echinacea, i.e., time 9 h. After 
treatment and prior to cervical tissue harvest, animals were euthanized with sodium 
pentobarbital (Sleepaway®, Fort Dodge Laboratories Inc., Burlingame, CA). 
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Figure 2 Illustration showing schedule of injections for pre-term labor model 
 
Development of Ex Vivo Model 
The rationale for using the ex vivo model, which was an entire cervical tissue excised 
from a non-pregnant ovariectomized mouse, was to study Echinacea’s anti-inflammatory 
activities under a more controlled environment (a 48 well microtiter plate) in which treatment 
conditions could be performed without interference from endogenous ovarian sex steroid 
hormones.  With this being the first study of its kind, the development of the ex vivo model 
and the subsequent treatments had to be optimized, and were performed as follows: 
Determination of optimal media for ex vivo studies: Two types of media were tested 
in order to determine the optimal medium for incubating ex vivo uterine cervical tissues.  
These included: HyClone RPMI [1640 1X with 2.05 ml L-glutamine (Thermo Scientific)], 
supplemented with 10% fetal bovine serum (Lonza Biowhittaker) and HyClone DMEM 
[High Glucose with 4.00 mM L-glutamine and 4500 mg/L glucose and sodium pyruvate 
(Thermo Scientific)], also supplemented with 10% fetal bovine serum (FBS) (Lonza 
Biowhittaker). The 0.1M PBS buffer only-treated group was used as a negative control. 
Harvested tissues were briefly rinsed in cold 0.1M PBS buffer and immediately placed into 
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their respective wells in a 48-well plate, with each well either containing 250 µl of: a). 0.1M 
PBS, b). DMEM, or c). RPMI.  The plates were incubated for 24 h in HERAcell 150i CO2 
incubator (set at 5% CO2) at 37°C (Thermo Scientific). At the end of the 24 h period, all 
tissues were harvested and either stored at -80°C for molecular analysis (real time PCR and 
Western blot analysis) or fixed in 10% formalin for histological analysis.  RPMI media was 
found to be the optimal medium, based on the morphological and molecular parameters, and 
thus was used in subsequent studies. 
Determination of optimal duration for tissue integrity, viability and survival in ex vivo 
model: Animals were divided into six treatment groups (n=1) and uterine cervical tissues 
were harvested, briefly rinsed in 0.1M PBS buffer and incubated, based on the six treatment 
groups in the 48-well plates, as described earlier. Uterine tissues were incubated for: 1 h, 4 h, 
8 h, 12 h, 16 h or 24 h, harvested and either fixed in 10% formalin for histological analysis or 
stored in -80°C for molecular analysis.   
Determination of optimal dosage and time for Echinacea and LPS: Uterine cervical 
tissues were harvested from mice, then the optimal time and dosage for Echinacea and LPS 
treatments (n=3) for the ex vivo model were determined.  To determine the optimal time for 
incubating, tissues in the negative (only vehicle, i.e., 0.1M PBS buffer) and LPS alone (LPS, 
1µg per well) control groups were incubated in the 48 well plates for 6 h, 12 h and 24 h. 
Tissues were then harvested and stored at -80°C, processed for and examined using real-time 
PCR and Western blot analysis. The 6 h incubation was determined to be the optimal 
duration, based on the molecular data and was, therefore, used in section 2 (optimal dosage). 
To determine the optimal dosage for the incubations, tissues were incubated for 6 h under 
varying treatment conditions.  There was an Echinacea only group (0.1 mg/well), and a dose 
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response group, namely Echinacea [0.01 (low), 0.1 (medium) or 1.0 (high) mg/well)] + LPS 
(1 μg per well), added an hour later, as well as a negative control (media only) and an LPS 
only group (1 μg per well). Tissues were then harvested 6 h post LPS treatment, after which 
they were stored at -80°C, and examined later using real-time PCR and Western blot 
analysis.  
For all subsequent ex vivo model experiments, the following optimal parameters were 
utilized: 6 h incubation, 1 µg of LPS per well and 1.0 mg of Echinacea per well. 
 
Mechanism of Action (In vivo, non-pregnant mice)  
 In order to determine whether HO-1 mediates Echinacea’s anti-inflammatory 
activities in the cervix of mice treated with LPS, the HO-1 inhibitor zinc protoporphyrin, 
(ZnPP) was used to test if it can attenuate HO-1’s anti-inflammatory mediatory actions in a 
dose-dependent manner.  Mice were divided into six treatment groups, with all treatments 
administered via IP, in 50 μl per mouse (n=3), as described here: negative control (ZnPP 
vehicle only, i.e., only 1% DMSO); LPS only (100 μg LPS), ZnPP only control (0.125 
mg/mouse), low ZnPP + Echinacea + LPS [ZnPP, 0.0125 mg/mouse; Echinacea, 1 
mg/mouse; LPS,100 μg of LPS per mouse], medium ZnPP + Echinacea + LPS [ZnPP, 0.125 
mg/mouse; Echinacea and LPS dosages, same as in sections above],  high ZnPP + Echinacea 
+ LPS [ZnPP, 1.25 mg/mouse; Echinacea and LPS dosages, same as described above]. 
Treatment groups that received Echinacea were administered first with Echinacea extract 
(one injection), as well as ZnPP (one injection), followed two hours later by LPS (100 
μg/mouse) and two hours post-LPS injection, the mice were euthanized. Cervical tissues 
were then harvested and stored at -80°C, and examined later using Western blot analysis. 
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Techniques Used in the Study 
Harvested tissues were processed appropriately and analyzed using gene (real time PCR) 
and protein (Western blot) expression techniques, as well as basic histology (H&E staining), 
as described below: 
Gene expression studies (real time PCR):  Gene expression analysis was performed using 
qRT-PCR to determine the extent to which Echinacea influenced mRNA expression of pro-
inflammatory factors such as IL-6 and COX-II as well as HO-1 in the cervix of both pregnant 
and non-pregnant mice.  Gene expression analysis was performed in three steps, as described 
below:   
 Tissue processing, messenger RNA isolation, and quantification:  Following 
treatments, animals were euthanized and trans-cardially perfused with normal saline (0.9% 
sodium chloride).  The cervices were harvested immediately, snap-frozen and either 
processed or stored at -80ᵒC until processing. Total RNA was isolated from individual 
cervices using the RNeasy Mini Kit (Qiagen, Valencia, CA) and then the quality and quantity 
of each sample was estimated using Nanodrop Spectrophotometer (NanoDrop 3000, Thermo 
Scientific).  Aliquots of total RNA were diluted in RNase-free deionized (DI) water and 
either stored at -80ᵒC or processed for reverse transcriptase PCR.  
 Reverse transcriptase PCR (RT-PCR): Total RNA from the cervical tissue was 
reverse-transcribed and amplified in an Eppendorf Master Cycler (Hamburg, Germany) using 
reagents from Applied Biosystems (Foster, CA). For generation of complementary DNA 
(cDNA), 1.0 µg of previously isolated total RNA was placed in a total volume of 9.5 µL per 
sample with RNase-free water, as determined by Nanodrop Spectrophotometer. The RNA 
incubated for 5 minutes at 65°C and cooled to room temperature for 10 minutes. During the 
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cooling period, 9.5 µL of a reverse transcriptase master mix was added to each tube, which 
was comprised of the following: reverse transcriptase buffer (2 µL per tube of RNA; Applied 
Biosystems, Foster, CA); MgCl2 (2 µL per tube of RNA; Applied Biosystems, Foster, CA), 
dNTP (2 µL per tube of RNA; Applied Biosystems, Foster, CA); RNase inhibitor (0.5 µL per 
tube of RNA; Applied Biosystems, Foster, CA); RNAse-free water (2µL per tube of RNA; 
Applied Biosystems, Foster, CA); and random hexamers (1 µL per tube of RNA; Applied 
Biosystems, Foster, CA). Lastly, 1.0 µL of MuLV reverse transcriptase (Applied Biosystems, 
Foster, CA) was added to each tube. One tube did not receive reverse transcriptase enzyme, 
and therefore served as a non-template control for DNA contamination. The Thermocycler 
was programmed to run at 25°C for 10 minutes, 42°C for 2 hours, 95°C for 5 minutes, and 
stored at 4°C. The generated total cDNA was then used to evaluate mRNA levels of the 
genes of interest.  
 Real-time PCR (qRT-PCR):  Relative expressions of the genes of interest [IL-6, TNF, 
COX-II] were evaluated using qRT-PCR. TaqMan® Gene Expression Assays (Applied 
Biosystems, Foster, CA), which are pre-designed and pre-optimized gene-specific probe sets, 
were utilized and DNA amplification was performed using the Applied Biosystems qRT-
PCR machine (ABI 7300 HT) with the GeneAmp 7300 HT sequence detection system 
software (Perkin-Elmer Corp.) The PCR reactions were set up in wells of 96-well plates in a 
volume of 25 μL per well. The reaction components included: 1000 ng (5.0 μL) of 
synthesized cDNA; 12.5 μL of 2X Taqman® Universal PCR Master Mix; 1.25 μL of 20X 
Assays-on-DemandTM Gene Mix (e.g. TNFα); and 6.25 μL of qRT-PCR-grade RNAse-free 
water. The program was set as follows: an initial step of 50ᵒC for 2 min and 95ᵒC for 10 min 
and then 40 cycles of 95ᵒC for 15 s and 60ᵒC for 60 s. The relative amount was calculated 
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from the threshold cycles with the instrument’s software (SDS 2.0) according to the 
manufacturer’s instructions. Relative expression levels of the target genes were normalized to 
the geometric mean of the endogenous control gene, GusB. 
 
Protein expression studies (Western blot):  Protein expression studies were performed using 
Western blot for quantification of the proteins of interest in order to determine the extent to 
which Echinacea influences the protein expression of various key pro-inflammatory factors 
(IL-6 and COX-II), as well as activity of phosphorylated NFκB and HO-1 in the uterine 
cervix of mice with or without LPS-induced inflammation, as described below: 
Protein Extraction:  Protein was extracted from cervical tissue using CellLytic
TM
 M 
Cell Lysis Reagent (Sigma Aldrich) and protease inhibitor cocktail (Sigma Aldrich).  Tissues 
were weighed individually, with lysis buffer calculated per tissue (1 g tissue: 20 ml buffer).  
Tissues were placed into pre-chilled conical tubes and mechanically homogenized in the 
buffer for 1-1.5 minutes, washing the homogenizer with distilled water in between uses.  
Once tissues were homogenized, tubes were centrifuged for 10 minutes at 20,000 xg at 4ᵒC.  
Once centrifuged, the supernatant was transferred to a pre-chilled eppendorf tubes and stored 
in -80ᵒC freezer until ready for use.  
 BCA Protein Assay:  Once protein was extracted from the individual cervical tissues, 
a BCA assay was run to quantify protein concentration.  Using a Pierce BCA Protein Assay 
Kit (Thermo Scientific, USA) protein standards made up of varying concentrations of 
albumin and distilled water were made in eppendorf tubes, as was a working reagent (25 ml 
Reagent A, 500 µl Reagent B).  Protein sample concentrations in either 1:10 or 1:5dilutions 
were made in eppendorf tubes.  A 96 well micro plate was loaded with each standard in 
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triplicate (25 µl per well) and protein samples were loaded in triplicate (25 µl per well).   
After loading the plate, 200 µl of working reagent was added to each well.  The plate was 
then incubated at 37ᵒC for 30 minutes.  At the end of the 30 minutes incubation period, the 
plate was read in a spectrophotometer (Thermo Scientific, USA) at 562 nm, giving protein 
concentrations in ng/µl.   
 Gel Electrophoresis:  Once protein sample concentrations were quantified via BCA 
assay, sample proteins were prepared for gel electrophoresis.  The volume of 10 µg of sample 
protein was calculated using values generated from the BCA assay.  Once protein volume 
was calculated, volume of distilled water was also calculated [10 µl Total in well – desired 
protein volume (µl) – 2.5 µl (Sample buffer) – 1.0 µl (reducing agent)].  NuPage LDS 
Sample Buffer (4x) was added to each tube, followed by the correct amount of distilled 
water.  Protein samples were then vortexed prior to the addition of the calculated volume of 
protein.  Once tubes had all their respective solutions added, they were vortexed for 10-15 
seconds before being centrifuged for 30 seconds (or until all liquid had settled at the bottom 
of the tube).  Tubes then sat at room temperature while the electrophoresis chamber was set 
up.  While setting up the chamber, we first removed the pre-made gel from its plastic before 
taking off the comb and white tape; then the wells were flushed via pipette with running 
buffer.  The gels were then loaded into the electrophoresis apparatus, with the clamp down.  
We then carefully poured a small amount of 1x NuPage running buffer in between the two 
gels before making sure there were no leaks.  If there were no leaks, running buffer was 
added halfway up the chamber before adding 500 µl of NuPage Antioxidant; once 
antioxidant was added, the remainder of the chamber was filled with running buffer just 
above the wells.  At this time, the electrophoresis chamber set up was complete, so we 
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incubated protein samples in the water bath at 65ᵒC for 10 minutes.  While the protein was 
incubating, 1.3 µl of ladder was loaded into the gels into their designated wells (dependent on 
the gel map designated for each particular gel).  After incubation but before loading of 
protein samples, we added 1.0 µl of NuPage Reducing Agent to sample tubes.  Then we 
loaded the 10ul samples consisting of protein, distilled water, sample buffer and reducing 
agent to each well.  After the gels were loaded, the outer chambers were filled with running 
buffer.  Gels were then run at 125 volts for approximately 1 hour (we stopped once the blue 
dye was about to the bottom of the gels).  The final step in the gel electrophoresis process 
involves the use of an iBlot machine. The first step was to set up the machine by putting the 
bottom cathode on the bottom and soaking a piece of filter paper in distilled water until the 
gel was ready.  Gels were removed from the electrophoresis chamber one at a time, and using 
the spatula provided, the cassette was slowly peeled off being careful not to tear the gel; then 
the tops of the wells were cut off to form a nice square shape.  The gel was then placed above 
the bottom cathode (cassette up, gel facing down) and slowly transferred from the cassette to 
the bottom cathode.  Once the gels were placed onto the bottom cathode, making sure no 
loose pieces of gel were on top or around the gel, filter paper was placed on top of the gel, 
with the air bubbles rolled out using the rolling pin.  The top cathode was then removed from 
its packaging and placed on top of the filter paper (shiny side up), with all the bubbles rolled 
out with the rolling pin.  At this point we placed the sponge on top with the metal part of the 
sponge touching the metal part of the iBlot.  The machine was then latched shut and a red 
light shined indicating proper assembly of the apparatus.  The machine was set to P3, 7:00, 
and then ran for 7 min.  At the end of the 7 min run time, the sponge and top cathode were 
removed, exposing the filter paper, which was removed carefully.  At this point, before 
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removing the gels, a razor blade was used to cut the membrane apart separating both 
membranes, and then slowly and carefully the gels were removed.  Next the membrane was 
submerged in blotto and incubated overnight in 4ᵒC. 
 Primary Antibody Incubation:  During this stage of western blot analysis, primary 
antibodies were diluted to the appropriate dilutions previously optimized in our lab as 
suggested by the manufacturer [Santa Cruz Biotechnology, USA (NFKB 1:500, IL-6 1:1000. 
COX-II 1:500, Beta-actin 1:1000)] and added 2 ml per membrane; 1 ml front, 1 ml back.  
Using plastic sandwich bags, small bags were prepared for the membrane and primary 
antibody.  The membrane was then removed from blotto and put into the middle of the bag 
with one end towards the spine of the bag.  As antibody dilution accuracy is key, it was 
important to remove as much blotto as possible without drying out the membrane.  Next, 
both sides of the bag were sealed before primary antibody was pipetted into the bag (1 ml in 
the front, 1 ml in the back).  Before sealing the top of the bag, all air bubbles were removed.  
Once the top was sealed, the membrane was placed on a shaker with a heavy flat surface on 
top (such as a huge text book) to ensure even distribution of the antibody.  The membrane 
was then left overnight on the shaker. 
 Secondary Antibody Incubation and Imaging:   Once membranes were allowed to 
incubate overnight with primary antibody, we removed them from the shaker and removed 
the membrane from its bag into a small container containing 1x TBST for a 10 minute wash.  
The membrane was then washed twice more for 10 minutes each after the initial wash.  
During the wash period, the secondary antibodies were diluted to the appropriate dilutions 
previously optimized in our lab as suggested by the manufacturer [Santa Cruz 
Biotechnology, USA (NFKB 1:10,000, IL-6 1:10,000. COX-II 1:10,000, Beta-actin 
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1:10,000)]).  Sandwich bags were once again used to make bags for the membrane and 
secondary antibody to be incubated in.  After the third wash in 1x TBST, the membrane was 
placed in the middle of the open bag, with both sides sealed (as described for primary 
antibody incubation).  Secondary antibody was pipetted in (1 ml in front, 1 ml in the back).  
Before sealing the top of the bag, all air bubbles were removed.  These membranes were then 
placed on a shaker underneath a heavy textbook for one hour.  After the hour long incubation 
period, the membrane was removed from the bag and washed in 1x TBST for 20 minutes.  
After the initial wash, the membrane was washed twice more in 1x TBST for 10 minutes 
each wash.  After the three washes in 1x TBST, the membrane was washed in 1x TBS for 10 
minutes.  During this last wash, the developer was booted up according to manufacturer’s 
instructions.   While membranes were washing we prepared a peroxidase/luminol enhancer 
solution in the dark, as this solution is light sensitive (2 ml peroxidase solution, 2 ml of 
luminol/enhancer solution).  The solution was vortexed and kept in the dark.  Once all 
washing was complete, membranes were placed on saran wrap and 1 ml of 
peroxidase/luminol enhancer solution was added to each membrane, soaking for 5 minutes.  
At the end of the 5 minute period, membranes were picked up to drip off as much solution as 
possible without drying the membrane out.  The membrane was then placed on a new piece 
of saran wrap which was folded over to cover the membrane, being careful not to have any 
creases or bubbles.  The membranes were then places in a developing cassette and taken to 
the developer machine.   
 Developing Western Blot Membranes:  The developer is housed in a dark room.  
Water container was checked and verified to be empty prior to starting the development 
process.  The machine was further prepared for use following manufacturer’s instructions.  
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Once the machine was ready to use, we exposed the membranes onto photo paper for varying 
increments of time.  Once this designated time period had passed, the photo paper was 
removed from the developing cassette and placed into the developer.  Once the paper 
completed its run through the developer, we were able to take the film which now showed 
bands of protein indicative of each target proteins; we were able to quantify the changes in 
protein expression as compared to beta-actin using ImageJ (National Institute for Health, 
USA) for analysis.    
 
Basic Morphological Studies (Hematoxylin and Eosin staining, H & E):  Experiments were 
undertaken to examine the basic histology of uterine tissues following various treatments 
described earlier. Frozen sections were stained with the standard H & E staining procedure 
(VWR international LLC, USA) and imaged using Olympus DSU IX81 (Olympus, USA) to 
examine the overall tissue structure, their characteristics and cellular subpopulations and 
blood vessels.  
 
Statistical Analysis 
Data were analyzed using Student's t test and ANOVA (single factor). p-values equal to or 
less than 0.05 were considered to be statistically significant. 
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Results 
 In order to determine whether Echinacea inhibits infection-induced inflammation in 
the cervix, three animal model systems were utilized, including a non-pregnant 
ovariectomized in vivo model, a pre-term labor model and an ex vivo model. These animal 
models are complementary, with the advantages and disadvantages of each model outlined in 
Figure 3.  
 
 
Figure 3 Comparison of three model system 
 
Echinacea suppresses the activity of NFκB in the cervix of non-pregnant in vivo model 
system. 
 We used the non-pregnant in vivo model, as this was the most commonly used model 
in our lab at the time.  Here, we investigated the effects of Echinacea on the levels of 
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activated (phosphorylated) NFκB.  In the experiments where we examined NFκB, we used 
protein expression as an indicator of activity, as phosphorylation is indicative of activity.  
Our hypothesis is that Echinacea regulates LPS-induced transcription of pro-inflammatory 
factors by reducing the levels of activated NFκB, such as IL-6 and TNFα.  For this 
experiment, the control (C) was only treated with 0.9% NaCl for baseline levels.  LPS was 
used as a positive control, as it robustly simulates infection-induced inflammation.  Finally, 
the treatment group was initially administered Echinacea followed four hours later by LPS, 
in order to determine whether Echinacea can effectively block LPS-induced NFκB activities.  
The results from this experiment show that animals treated with 0.9% NaCl alone exhibited 
baseline levels of p-NFκB, whereas LPS-treated animals (LPS 100 µg, IP) showed a 
significant increase in p-NFκB levels compared to control.  Echinacea administered prior to 
LPS treatment, revealed a 4 fold (p= 0.0256) decrease in p-NFκB protein levels compared to 
LPS alone, showing p-NFκB levels were significantly inhibited by Echinacea compared to 
LPS alone (Appendix, Figure 4).  
 
Echinacea down regulates expression of pro-inflammatory factors (COX-II and IL-6) in 
the cervix of preterm labor mouse model 
 Having shown Echinacea’s ability to suppress NFκB activity in the non-pregnant in 
vivo model, we wanted to test whether the preterm in vivo model would yield similar results 
when all confounding factors – sex steroid hormones, adrenal hormones, and adipose tissue – 
were present.  Since IL-6 levels in preterm labor increase, we sought to investigate whether 
Echinacea could suppress LPS-induced levels of IL-6 mRNA and protein, in our preterm 
labor in vivo model, which is normally associated with increases in matrix metalloproteinases 
that are responsible for degradation of collagen in the cervix during cervical remodeling.  We 
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also looked at COX-II mRNA because COX-II is responsible for the conversion of 
arachidonic acid to prostaglandins, which stimulates myometrial contractions and ultimately 
ripening of the uterine cervix.  Successful suppression of these two pro-inflammatory factors 
(IL-6 and COX-II) by Echinacea could imply its potential for modulating inflammation-
induced cervical remodeling.  The negative control (C) in this experiment was treated as 
described above, however for the positive control (LPS only) and the treatment group 
(Echinacea + LPS) a higher dose of LPS (250 μg/mouse) was administered. Here, we show 
that Echinacea, sharply inhibits IL-6 mRNA and protein levels by 11 (p= 0.00019) and 2.2 
fold (p=0.0297), respectively (Appendix, Figure 5a-b).  We also show that Echinacea 
robustly inhibits COX-II mRNA levels by almost 200 fold (p= 0.000258).   
 
Tissue integrity, viability and the anti-inflammatory activities profile of Echinacea in 
the ex vivo model system 
 Having characterized some of Echinacea’s anti-inflammatory properties both in non-
pregnant and pregnant in vivo models, we wanted to develop a model that could potentially 
eliminate the confounding factors seen in both in vivo models (sex steroids, adrenal 
hormones, adipose tissues).  This led to the development of an ex vivo model, in which the 
entire cervical tissue was excised from the animal post-ovariectomy, with all treatments 
conducted in a microtiter plate.  In this particular experiment, we first wanted to make sure 
the ex vivo model was a suitable model for evaluating Echinacea’s anti-inflammatory effects 
on cervical tissue, so we compared the cervical histomorphology of hematoxylin and eosin 
(H&E)stained tissues from non-pregnant in vivo and ex vivo models.  Comparisons were 
based on tissue integrity and the cell types (epithelial cells, stromal cells, +/- immune cells) 
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present.  The negative and positive controls, as well as Echinacea treatment in the non-
pregnant in vivo model were performed as described earlier (see above), whereas in the ex 
vivo model, the negative control was vehicle-treated only (RPMI 1640), while the LPS 
treatment was ten-fold lower than the in vivo model (1 μg/well), and Echinacea treatment 
was 1 mg/well.  We show the presence of epithelial and stromal cells, indicative of tissue 
structure.  We also show that the Echinacea and LPS treated tissues look more like the 
negative control than the LPS only treated group, showing support for Echinacea combating 
the effects of LPS on these tissues (Appendix, Figure 6A-F). 
 After confirming the proof of principle for the ex vivo model, showing that tissues 
remain viable after being removed from the body, we wanted to test Echinacea’s ability to 
decrease LPS-induced levels of IL-6 and COX-II in the ex vivo model, and compare the 
results to what we saw in the preterm in vivo model.  The experimental treatments were as 
described before, except addition of a group treated with Echinacea only, to study the effects 
of Echinacea alone compared to control or baseline levels of IL-6 and COX-II mRNA.  We 
show that Echinacea significantly decreased LPS-induced IL-6 mRNA levels compared to 
LPS alone by 2.6 fold, with no statistical difference between the Echinacea alone treatment 
and the Echinacea and LPS treatment groups (Appendix, Figure 7a).  The same trend was 
noted with COX-II mRNA levels, with a fold change of 1.8 (Appendix, Figure 7b).  No 
significant difference was noted between Echinacea alone group and the negative controls, 
for both pro-inflammatory factors. 
 Thus far, we have demonstrated Echinacea’s ability to inhibit expression of LPS-
induced IL-6 and COX-II mRNA in both the in vivo preterm and ex vivo non-pregnant 
model, as well as the levels of p-NFκB in the non-pregnant in vivo model.  Next, we sought 
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to investigate whether Echinacea could diminish p-NFκB levels in an ex vivo model.  
Cervices were essentially treated as described earlier, except for the addition of a dose-
dependent treatment of Echinacea (doses ranging from 0.01 mg/well – 1.0 mg/well), with 
LPS dosage unchanged.  Here, we show that Echinacea inhibits LPS-induced activation of 
NFκB, in a dose-dependent manner, with the medium and highest concentration of 
Echinacea decreasing p- NFκB levels 2 and 3 fold, respectively, compared to LPS alone 
(p=0.0287) (Appendix, Figure 8). We chose to use the highest dose, however, as these 
findings were consistent with our earlier observation in the non-pregnant in vivo model 
(Appendix, Figure 8). 
 
Echinacea shows a down-regulatory effect on HO-1 protein (preterm in vivo model) and 
HO-1 mRNA (non-pregnant ex vivo model)  
 We investigated Echinacea’s effects on HO-1 protein and mRNA using both the 
preterm in vivo and non-pregnant ex vivo models, respectively.  Animals were treated as 
previously described for both the preterm in vivo and non-pregnant ex vivo models.  We show 
in the preterm in vivo model that Echinacea:  a) decreased HO-1 protein levels compared to 
LPS alone, and b) combined with LPS significantly elevated levels of HO-1 protein 
compared to the negative control (Appendix, Figure 9A).  We observed similar results from 
our non-pregnant ex vivo model, showing Echinacea a) decreases HO-1 mRNA levels 
compared to LPS alone, and b) combined with LPS significantly elevated levels ofHO-1 
mRNA compared to the negative control (Appendix, Figure 9B).   
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HO-1 inhibitor blocks Echinacea’s down-regulatory effect on NFκB 
Thus far, we have demonstrated Echinacea’s effects on HO-1 mRNA and protein 
expression in both the non-pregnant ex vivo and preterm in vivo models, respectively.  Next, 
we sought to further confirm Echinacea’s ability to induce HO-1 activity by investigating the 
effects of blocking HO-1 on levels of p- NFκB, using our non-pregnant in vivo model.  
Animals were essentially treated as previously described, except for the addition of a ZnPP 
only treatment, as well as a dose-dependent treatment of ZnPP (doses ranging from 0.0125 
mg/mouse to 1.25 mg/mouse) with Echinacea and LPS doses unchanged.  Animals treated 
with ZnPP, Echinacea, and LPS together showed an increase in levels of p- NFκB in a dose-
dependent manner, with the highest dose of ZnPP exhibiting a 2 fold increase from the 
negative control.  We also show a significant inhibition of activated levels of p- NFκB by 
ZnPP alone (Appendix, Figure 10). 
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Discussion 
 The purpose of the present study was to examine the ability of Echinacea to down-
regulate the expression of LPS-induced pro-inflammatory cytokines in mice cervix and its 
likely underlying mechanisms. The key findings of the study are that Echinacea:  1) 
attenuates expression of certain cytokines associated with precocious cervical remodeling 
(IL-6, COX-II), in three animal models, including non-pregnant in vivo, ex vivo and preterm 
labor models, 2) diminishes the activity of the master transcription factor of classical pro-
inflammatory cytokines, NFκB (phosphorylated), 3) promotes the expression of HO-1 in 
mice cervix, and that 4) HO-1 inhibitor blocks Echinacea’s attenuating effects on the levels 
of p-NFκB in the cervix, in a dose dependent manner.  These data suggest that the NFκB 
inhibitory activity of Echinacea is at least in part, mediated by up-regulation of the 
inflammatory mediator HO-1 by Echinacea.  The present study is the first to provide 
evidence for Echinacea’s anti-inflammatory activity and its likely underlying mechanism in 
the cervix. These data may prove useful in developing therapies that can be used to prevent 
and modulate inflammation-induced preterm labor. 
Microbial infection and the subsequent precocious and abnormal presence of 
inflammatory factors, including TNFα, IL-1 and -6, are known to induce premature uterine 
contractions and birth canal opening (Rizzo et al. 1996, Raso et al. 2002, Menon & Fortunato 
2007) and, ultimately, premature birth (Rizzo et al. 1996, Alderem & Ulevitch 2000, Beutner 
2000, Zhang & Ghosh 2001, Menon & Fortunato 2007).  When LPS, a cell wall component 
of gram negative bacteria, binds to white blood cells (WBCs) expressing its receptor [toll-
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like receptor 4 (TLR4)], it activates NFκB and, subsequently, increases the expression of the 
downstream pro- and or anti-inflammatory cytokines (TNFα, IL-6 and IL-10) (Alderem & 
Ulevitch 2000, Beutner 2000, Zhang & Ghosh 2001).  Because the female reproductive tract 
(from fallopian tubes to vagina) richly expresses LPS receptor subtypes (TLR 1-6), it is 
endowed with an extensive immune surveillance, which plays a vital role in defense against 
infection (Pioli et al 2004). Importantly, since preterm labor initiation can be triggered either 
in the cervix or upstream of it, i.e., uterus, this (presence of TLR) also implies that Echinacea 
may act not only on the cervix, but also the rest of the female reproductive compartments. 
Notable pro-inflammatory cytokines associated with preterm labor in humans include IL-6 
and TNFα, among others (Rizzo et al. 1996). For instance, in one study, of the 20% of 
subjects (women) that had microbial infection and abnormally elevated levels of IL-6 in the 
amniotic cavity and cervical secretions, 100% experienced preterm labor (Rizzo et al. 1996). 
IL-6 activates the immune system through its receptor complex, IL-6Rα and gp130 
(Kamimura et al. 2004), which in turn activate downstream transcription factors, such as 
STAT3 and MAPK (Kishimoto et al. 1995). Another key factor induced by infection is 
COX-II, the enzyme responsible for converting arachidonic acid to prostaglandins, which 
play an important role during labor (Gross et al. 2000). These pro-inflammatory factors are 
expressed in a variety of female reproductive tissues, including myometrium, fetal 
membranes and the cervix before and after labor (Young et al. 2002).  In the same study, 
Young et al (2002) showed that invading leukocytes secrete pro-inflammatory cytokines in 
multiple reproductive tissues, notably the myometrium, cervix, placenta, and fetal 
membranes, including IL-1β, IL-6, IL-8, and TNFα in biopsies taken after labor than in those 
obtained before labor (Young et al 2002).  Most importantly, an increase in IL-6 
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concentrations in cervicovaginal fluid (most likely from leukocytes) has been observed 
during labor at term and preterm (Young et al. 2002).  There is also support for the cytokines 
themselves acting as mediators of leukocyte recruitment at term, in a positive feed-forward 
manner – i.e., cytokines mediate leukocyte infiltration and the leukocytes in turn produce 
more cytokines, ultimately stimulating uterine contractions by inducing prostaglandin 
production (Young et al. 2002).  Taken together, the strong link between inflammation and 
preterm labor, and the ability of Echinacea to modulate pro-inflammatory factors, makes the 
present findings of potential clinical importance. 
 Medicinal plants have been used in various regions of the world for several centuries, 
including North America (Foster 1991, Hutchens 1992, Flannery 1998). However, the 
development of modern synthetic chemistry and target screening assays led to a sharp decline 
in the pursuit of herbal remedies (Binns et al. 2002, Woelkart et al. 2008, Altamirano-Dimas 
et al. 2009, Hudson 2012).  Recently, there has been renewed interest in herbal remedies by 
the general public in North America, with Echinacea topping the list (Cavaliere 2009). 
Correspondingly, there has been an increase in the number of studies that have characterized 
various biological activities of Echinacea, particularly its anti-inflammatory effects.  For 
instance, studies have shown that Echinacea attenuates expression of virus-induced pro-
inflammatory cytokines by neutralizing rhinovirus 1a (RV1A)-induced cytokine secretion 
(Sharma et al 2009b), including an almost complete inhibition of IL-6 and TNFα activities at 
a dose of 40 μg/ml of Echinacea extract (Sharma et al 2009b).  Also, when murine RAW 
264.7 macrophage cells, a cell line that is commonly used for studying lipid metabolism, 
inflammation and apoptosis, were activated to secrete high levels of pro-inflammatory factors 
using LPS, Echinacea extracts inhibited the levels of the pro-inflammatory factors [TNFα, 
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nitric oxide (NO), and inducible NO synthase (iNOS)] (Zhai et al. 2009), dose-dependently.  
Of note, Echinacea does not only inhibit LPS-induced inflammation, but also other 
inflammation-inducing irritants, such as carrageenan and croton oil.  Specifically, Echinacea 
administered intravenously attenuated carrageenan- and croton oil-induced rat paw edema 
and mouse ear tests (Barnes et al. 2005). Collectively, the present data are consistent with 
these previous data, and indicate that Echinacea can modulate inflammation in different 
tissues of the body. 
Echinacea’s ability to reduce inflammatory cytokines has been demonstrated in a 
variety of in vivo and in vitro models.  For instance, the effects of the three commonly used 
Echinacea species, E. angustifolia, E. pallida, and E. purpurea, both in vivo and in vitro, to 
inhibit the production of inflammatory mediators – such as nitric oxide (NO), TNFα and IL-
1β in activated macrophages, has been demonstrated (Zhai et al. 2007).  Another study using 
an in vitro model sought to test the effects of Echinacea treatment and rhinovirus infection 
on the activation of transcription factors in the BEAS-2B human bronchial epithelial cell line 
(Sharma et al. 2006).  The findings from this study showed an increase in 12 different 
transcription factors by both Echinacea extracts (uninfected) from basal levels and a decrease 
in transcription factors by both Echinacea extracts when infected with rhino virus – most 
dramatically with STAT4 and NFκB (Sharma et al. 2006).  This implies that Echinacea can 
act to down-regulate specific transcription factors associated with inflammation (Sharma et 
al. 2006).  Another study using BEAS-2B human bronchial epithelial cells looked at the 
effects of Echinacea treatment and rhino virus infection on pro-inflammatory cytokines IL-6 
and IL-8 (Sharma et al. 2009a).  This study found rhino virus induced IL-6 and IL-8 
increases can be reversed by Echinacea (Sharma et al. 2009a).  Other models have also been 
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studied.   For example, male BALB/c mice were used in a study conducted by Raso et al, 
where the anti-inflammatory effect of Echinacea was evaluated against carrageenan-induced 
paw edema in mice (Raso et al. 2002).  Mice were treated by gavage with Echinacea three 
days before injection with carrageenan and 72 hours post-injection (Raso et al. 2002).  This 
study found Echinacea to significantly inhibit edema and decrease COX-II and inducible 
nitric oxide synthase (iNOS), as well as inhibition of LPS-induced COX-II expression in 
peritoneal macrophages (Raso et al. 2002).  Another study using peripheral blood 
mononuclear cells (PBMC) attempted to track down the molecular method of action of 
Echinacea (Gertsch et al. 2004).  In this particular study, cells treated with Echinacea alone 
showed an increase in TNFα, β-actin and IL-8, with a marked decrease in IL-2 levels; 
however, Echinacea did inhibit LPS-mediated TNFα protein levels (Gertsch et al. 2004).  
Alkylamides, one of the bioactive constituents in all Echinacea ethanolic extracts, were 
found to significantly inhibit TNFα protein expression, as well as LPS-induced increase in 
NFκB activity (Gertsch et al. 2004).  This study suggested that the effects of Echinacea are 
mediated by cannabinoid receptor CB2 and modulation of cyclic adenosine monophosphate 
(cAMP), activation of JNK and p38 MAP kinases, as well as downstream activation of NFκB 
(Gertsch et al. 2004).  It is this final study, perhaps, that is most important to the present 
study.  Not only does it show marked inhibition of LPS-induced NFκB activity, but also 
attributes the activity to alkylamides, which are bioavailable in plasma following oral 
ingestion of Echinacea (Toselli et al. 2009).  Taken together, all of these studies show strong 
support for Echinacea (specifically alkylamides) as a modulator of inflammation.  
Here, we also examined Echinacea’s effect on the enzyme HO-1, which has several 
anti-inflammatory links, but has not been reported previously in reproductive tissues 
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(Zenclussen et al. 2011).  HO-1 is the rate limiting enzyme that breaks down heme from 
degraded red blood cells into carbon monoxide (CO), biliverdin, and free iron (Otterbein et 
al. 2003), and is believed to exert its anti-inflammatory properties through these catabolic by-
products (Nath et al. 1992,Willis et al. 1996, Lee & Chau 2002, Otterbein et al. 2003). 
Indeed, mice lacking HO-1 develop chronic inflammatory diseases (Kapturczak et al. 2004).  
In the liver, Echinacea-derived alkylamides promote expression of HO-1, and is believed to 
contribute to the hepato-protective effects against LPS-induced inflammation (Hou et al. 
2001), and infusion of the HO-1 inhibitor, ZnPP, in rats attenuates these beneficial hepato-
protective actions of HO-1, showing that HO-1 plays a protective role against 
ischemia/reperfusion injury, which is also associated with inflammation (Amersi et al. 1999).  
Further, Hou and others used murine macrophage cells to demonstrate that Echinacea-
derived alkylamides also induce expression of HO-1, which in turn inhibit expression of pro-
inflammatory cytokines (Hou et al. 2001). These earlier observations are consistent with our 
present data. In Figure 9, we show up-regulation of HO-1 mRNA (non-pregnant ex vivo) and 
protein (preterm in vivo) by Echinacea, which is consistent with previous studies; however, 
no significant difference in levels of both HO-1 mRNA and protein in cervices treated with 
Echinacea plus LPS compared to LPS alone were observed. This implies that LPS has no 
significant effect on Echinacea’s ability to up-regulate HO-1 mRNA and/or protein.  We also 
show that a known HO-1 inhibitor (Figure 10) attenuates Echinacea’s anti-inflammatory 
effects dose-dependently via up-regulating levels of activated or p-NFκB, implying that HO-
1 mediates Echinacea’s anti-inflammatory activities.  Data showing decrease of  p-NFκB 
levels by ZnPP alone compared to negative control levels was not expected and is for now 
unclear.  One possible explanation for this discrepancy could be post-surgery infection of the 
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negative control animals, which could account for the observed increase in levels of p NFκB 
compared to the ZnPP-only treated animals. However, more studies are required. 
Currently, our knowledge and understanding of HO-1’s action in reproductive 
biology is very limited. Notably, and of relevance to the current study, are reports that 
suggest that miscarriages in both human and mice, which are commonly triggered by 
microbial infection and inflammation (Menon & Fortunato 2007, Zenclussen et al. 2011), are 
associated with diminished local levels of HO-1. This implies that HO-1 may be an important 
player in modulating inflammation and the resultant loss of pregnancy. Further, this may 
perhaps explain why deletion of HO-1 leads to suboptimal placentation, as well as fetal 
lethality in mice. The present study is the first to demonstrate HO-1’s mediatory anti-
inflammatory activities for Echinacea in reproductive tissues in general, and cervix, in 
particular. These findings are of interest in that they show, for the first time, that Echinacea 
influences expression of a potentially important gene that may have broad reproductive 
functions, i.e., HO-1 does not only modulate inflammation, but also other key reproductive 
events associated with pregnancy, such as placental and fetal growth and viability 
(Zenclussen et al. 2011). 
We also report here development of an ex vivo model and demonstrate its suitability 
(tissue integrity and viability, and inflammatory response) as a bioassay for studying 
mechanisms and pathways underlying Echinacea’s anti-inflammatory activities. Although 
still in development, this model eliminates pregnancy-associated confounding variables by 
providing a tightly controlled environment, and will thus be especially useful as a target 
screening bioassay, as we attempt to follow, identify and isolate the exact extract 
candidate(s) in Echinacea responsible for the anti-inflammatory activities. This will be 
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accomplished through a series of sub-fractionation, chemical isolation steps and target 
screening. Data generated from this bioassay will then be used for the preterm labor mice 
model studies. We fully anticipate that isolated and concentrated sub-fractions and/or 
individual substances will induce higher and/or more prolonged anti-inflammatory activity 
on a per gram raw material basis. To date, whole hydro-ethanolic Echinacea has over 19 
bioactive isolated compounds that demonstrate anti-inflammatory activities, of note, luteolin, 
apigenin, caffeic acid, beta-sitosterol and limonene (Duke 1992).  Generally, according to 
recent reports, the most probable sub-fractions of Echinacea likely to mediate its anti-
inflammatory properties are alkylamides and polysaccharides (Clifford et al. 2002, Raso et 
al. 2002, Kraus et al. 2006, Hinz et al. 2007).  These compounds have been shown to 
influence multiple inflammatory signaling pathways and at various steps, including inhibiting 
the activity of IKKβ, interferon regulatory factor 3 (IRF3), and TLR3/TLR4-induced NFκB 
or IkB degradation (Lee et al. 2009).  The inhibition of these upstream factors decreases the 
activity of a plethora of downstream pro-inflammatory factors, such as TNFα, IL-6, IL-12, 
NOS, COX-II (PGE2) (Bouic & Lamprecht 1999, Shin et al. 2004, Ha et al. 2008, Lee et al. 
2009, Moon et al. 2009, Alappat et al. 2010, Loizou et al. 2010; Yoon et al. 2010).  Looking 
at Figure 5 and Echinacea’s effect on p-NFκB levels we see a strange increase in NFκB 
levels in cervices treated with low Echinacea prior to LPS compared to cervices treated with 
LPS alone.  Here, we expected levels to still be high compared to measurement of NFκB 
activity in the presence of a higher dose of Echinacea.  One possible explanation for this 
could be post-surgery infection in the mouse after ovariectomy that had not been resolved 
prior to excision of the cervix from the animal.  While the increase is strange, it does not 
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appear to be statistically significant compared to LPS alone, however conducting further 
studies may be necessary. 
In the present study, we use three different animal models that complement each 
other.  For example, in our preterm model, the response to LPS was seen in the 100 fold 
range, and Echinacea drastically reduced expression of pro-inflammatory cytokines, whereas 
in both non-pregnant in vivo and ex vivo models, the response to LPS treatment was mild, 
with only a 2-3 fold difference compared to Echinacea plus LPS.  On average, the Echinacea 
response was similar to the negative control (vehicle only, 0.9% NaCl).  This difference in 
the magnitude of response to infection between preterm and non-pregnant in vivo may reflect 
the differential influence of two major sex steroid hormones on inflammation: i.e., estrogen 
and progesterone.  While estrogen has anti-inflammatory activities, progesterone on the other 
hand is pro-inflammatory.  Therefore, one possible explanation for the remarkably high IL-6 
and COX-II mRNA levels in the preterm in vivo model (Figure 2) could be due to the 
influence of estrogen and progesterone on the expression of pro-inflammatory factors in the 
cervix (Pettipher et al. 1996, Deshpande et al. 1997, Kershaw & Flier 2004,  Gillgrass et al. 
2005, Nilsson 2007). 
In conclusion, we report a novel finding that Echinacea attenuates activity of NFκB and 
expression of its (NFκB) downstream pro-inflammatory cytokines, associated with infection-
induced preterm labor in the cervix of mice. We also developed an ex vivo cervical model 
and showed that the enzyme HO-1 could be one of the key mediators of Echinacea’s anti-
inflammatory effects in the cervix (see proposed working model, Figure 11). Through our 
working model (Figure 11) we propose that Echinacea acts through increasing transcription 
of HO-1 (perhaps via the p38 MAP kinase pathway) to block inflammation via up-regulation 
 
47 
 
of carbon monoxide, which in turn blocks transcription of pro-inflammatory factors via the 
NFκB signaling pathway.  These findings are significant in that they provide insight that 
could potentially lead to the development of natural strategies for modulating infection-
induced preterm labor. 
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Figure 4 Effects of Echinacea on phosphorylated NFκB in the cervix of in vivo non-
pregnant ovariectomized mice, as revealed by protein expression studies (Western 
Blot). Echinacea administered IP down-regulated levels of p-NFκB protein. Negative 
control (C) = vehicle only, 0.9% NaCl, IP; LPS alone = 100 µg, IP and Echinacea 
=1.0 mg/mouse, IP. n=3,** p < 0.05 LPS vs. C; *p < 0.05 E + LPS vs. LPS.  β-actin 
was used as a normalizer. 
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Figure 5 Effects of Echinacea on expression of IL-6 mRNA and protein, as well as COX-II 
mRNA in the cervix of preterm labor mice.  A) IL-6-mRNA and B) IL-6-protein, as revealed 
by real-time PCR (qRT-PCR) and Western blot analysis. Echinacea administered 2 times, IP, 
has a down-regulating effect on IL-6 mRNA levels and IL-6 protein expression compared to 
LPS only. n=3; * p < 0.05 LPS vs. C; **p < 0.05 E + LPS vs. LPS. β-actin was used as a 
normalizer in Western blot.  C) COX-II mRNA expression, as revealed by real-time PCR 
(qRT-PCR). Echinacea administered twice, IP, and has a down-regulating effect on COX-II 
mRNA levels compared to LPS only. n=3; *p < 0.05 E + LPS vs. LPS. 
* 
* 
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Figure 6 Histomorphogical profile of the cervix of non-pregnant ovariectomized mice 
treated in vivo (A-C) and ex vivo (D-F) mice treated with Echinacea, as revealed by H 
& E stain.  In vivo model: Tissues in Echinacea + LPS-treated animals (IP), closely 
resembles histology of negative but not LPS alone group. A) Negative Control 
(vehicle only, 0.9% NaCl, IP); B) LPS alone (100 µg, IP); C) Echinacea (1 
mg/mouse) + LPS (100 µg, IP).  Ex vivo model: As in the in vivo model above, 
Echinacea-treated cervices incubated in a 48-well plate resemble the histology of the 
negative control, but not the LPS alone treatment group. D) Negative Control (media 
only, 1640 RPMI); E) LPS alone (1 µg/well); F) Echinacea (1 mg/well) + LPS (1 
µg/well).  All images were taken at 20x. “e” =epithelia, while “L”=cervical lumen. 
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Figure 7 Effects of Echinacea on A) IL-6 and B) COX-II mRNA 
expression in the mice cervix of the ex vivo model (non-pregnant 
ovariectomized), as revealed by real time-PCR. Echinacea has a down-
regulating effect on IL-6 and COX-II mRNA levels compared to the LPS 
alone group.  Negative Control (vehicle only, RPMI 1640); LPS alone 
(LPS 1μg per well); Echinacea only (0.1 mg/well); optimal dose of 
Echinacea high (1.0mg/well) + LPS (1µg per well).  n=3,* p < 0.05 
E+LPS vs. LPS. 
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Figure 8 Effects of Echinacea on phosphorylated NFκB in the cervix of ex vivo non-
pregnant ovariectomized mice.  Echinacea down regulates the activity of NFκB, in the 
mice cervix of the ex vivo model, dose-dependently, as revealed by Western blot 
analysis.  Negative control=vehicle only (RPMI 1640); LPS only = 1μg per well; 
Echinacea only=0.1 mg/well; and Echinacea [low=0.01mg/well; 
medium=0.1mg/well; high=1.0 mg/well] + LPS (1μg per well). n=3,* p < 0.05 High 
E+LPS vs. LPS; β-actin was used as a normalizer. 
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Figure 9 Effects of Echinacea on HO-1 protein expression and mRNA levels in the 
mice cervix of the preterm in vivo and non-pregnant ex vivo models, respectively. 
Echinacea: A) administered I.P down-regulates HO-1 protein levels compared to LPS 
only in the cervix of preterm labor mouse model, as revealed by protein analysis 
(Western blot). Negative control=vehicle only, 0.9 % NaCl, IP; LPS alone (250 
μg/mouse, intrauterine); B) induces expression of HO-1 mRNA in an ex vivo non-
pregnant ovariectomized mouse model compared to control (negative), as revealed by 
Western blot and real time PCR, respectively. n=3;* p < 0.05 E+LPS vs. LPS; β-actin 
was used as a normalizer. 
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Figure 10 HO-1 inhibitor blocks Echinacea’s down regulatory effect on the activity 
of NFκB in cervix of mice treated with LPS as revealed by Western blot analysis.  
n=3;* p < 0.05 ZnPP vs. C. β-actin was used as a normalizer.  The table below the 
figure indicates the solutions present in each treatment group, with a + indicating that 
a particular solution was used while – indicates it was not.   
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Figure 11 Proposed working model of Echinacea in regulating expression of pro-
inflammatory factors in the cervix. Echinacea induces transcription of heme-
oxygenase-1, which in turn blocks transcription of pro-inflammatory factors via its 
heme byproduct, carbon monoxide (CO). 
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